Collectively, these data emphasize the pathogenicity of FBN1 in individuals with AD, and the clinical differences between FBN1 positive-variant carriers and non-FBN1 positive-variant (FBN1 negative-variant) carriers were also confirmed. This evidence concerns the gene FBN1 and Alzheimer disease.